News & Perspective

May 10, 2013

May 10, 2013

Experts offer dim view of potential vaccine response to H7N9

If the H7N9 influenza virus now circulating in China evolves into a pandemic strain, the world is likely to have great difficulty providing adequate supplies of an effective vaccine in time to blunt its impact, according to a viewpoint article by three experts in the Journal of the American Medical Association (JAMA).

Jan 17, 2013

Jan 17, 2013

FDA approves first flu vaccine grown in insect cells

(CIDRAP News) – The US Food and Drug Administration (FDA) has approved the first influenza vaccine produced with the help of an insect virus and recombinant DNA technology, an approach the agency says may make it possible to start production faster in the event of a flu pandemic.

Nov 21, 2012

Nov 21, 2012

FDA clears first cell-based flu vaccine

(CIDRAP News) – The US Food and Drug Administration (FDA) yesterday approved the nation's first cell-based flu vaccine, a product from Novartis that uses technology that could help vaccinate more Americans in a pandemic but still has many of the same limitations of older egg-based flu vaccines.

Oct 15, 2012

Oct 15, 2012

Report: Complacency, misperception stymie quest for better flu vaccines

The world needs much better influenza vaccines, but the quest for them faces a formidable barrier: overconfidence about the effectiveness of existing influenza vaccines.

Nov 15, 2007

Nov 15, 2007

THE PANDEMIC VACCINE PUZZLE Can we vaccinate enough people in time to matter?

Maryn McKennaContributing Writer

(CIDRAP News) – This in-depth article investigates the prospects for development of vaccines to head off the threat of an influenza pandemic posed by the H5N1 avian influenza virus. Its seven parts put advances in vaccine technology in perspective by illuminating the formidable barriers to producing an effective and widely usable vaccine in a short time frame.

Jan 17, 2007

Jan 17, 2007

HHS funds work on dose-sparing H5N1 vaccines

(CIDRAP News) – In an effort to stretch the nation's supply of vaccines for a potential influenza pandemic, federal health officials today announced contracts totaling $132.5 million to help three companies develop dose-sparing substances, or adjuvants, to be used with H5N1 flu vaccines.

Oct 17, 2006

Oct 17, 2006

Baxter says cell-based H5N1 vaccine shows potential in trial

(CIDRAP News) – Low doses of a cell-based avian flu vaccine triggered a good immune response to the H5N1 avian influenza virus, according to preliminary results of a clinical trial by Baxter International of Deerfield, Ill., maker of the vaccine.

Oct 05, 2004

Oct 05, 2004

Half of US flu vaccine supply suddenly not available

(CIDRAP News) – The vaccine supply for the soon-to-begin influenza season is suddenly in serious condition with news that Chiron Corp., maker of about half the US supply, has been ordered to stop production by British health authorities and will not be shipping its doses.

Sep 21, 2004

Sep 21, 2004

HHS awards contract for H5N1 avian flu vaccine

(CIDRAP News) – In a bid to limit the threat of an influenza pandemic, the Department of Health and Human Services (HHS) is awarding a contract to Aventis Pasteur Inc. to make 2 million doses of a vaccine for humans to protect against H5N1 avian influenza.

Newsletter Sign-up

Get CIDRAP news and other free newsletters.

Sign up now»

OUR UNDERWRITERS

Unrestricted financial support provided by

Bentson Foundation Gilead 
Grant support for ASP provided by


bioMérieux

  Become an underwriter»